FDA Panel To Decide Whether New Breast, Prostate Cancer Drugs Are Worth The Risks
Summary
FDA staff have expressed concerns about the use of camizestrant to treat metastatic breast cancer and capivasertib for patients with metastatic hormone-sensitiv...
Description
FDA staff have expressed concerns about the use of camizestrant to treat metastatic breast cancer and capivasertib for patients with metastatic hormone-sensitiv...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source